As a member of the protein kinase C family, PRKCI affects tumorigenesis, progression and chemosensitivity by regulating the Wnt/beta-catenin pathway and immune microenvironment in lung cancer, ovarian cancer and alveolar rhabdomyosarcoma [39–41]. This evidence concerns the gene PRKCI and rhabdomyosarcoma.